

Market Announcement

2 November 2023

BOD Science Limited (ASX: BOD) – Continuation of Suspension from Quotation

Description

The securities of BOD Science Limited ('BOD') were suspended from quotation under Listing Rule 17.5 on Wednesday, 1 November 2023 as BOD did not lodge its Full Year Statutory Accounts by the due date.

BOD has since lodged its Full Year Statutory Accounts, however BOD will continue to be suspended from quotation under Listing Rule 17.2, at the request of BOD, pending the release of an announcement regarding its capital raising.

Issued by

Lisa Banh

Senior Adviser, Listings Compliance



2 November 2023

ASX Compliance Pty Ltd
20 Bridge Street
Sydney NSW 2000

By email: tradinghaltssydney@asx.com.au

**Bod Science Limited (ASX: BOD)
Request for Voluntary Suspension**

Bod Science Limited ACN 601 225 441 (the **Company** or **Bod**) refers to the suspension from quotation under Listing Rule 17.5 which commenced on 1 November 2023, for not lodging the relevant periodic report by the due date.

Bod notes that the relevant periodic report was lodged on 1 November 2023.

Pursuant to Listing Rule 17.2, the Company requests a voluntary suspension of trading in its securities from the commencement of trading today, 2 November 2023.

In accordance with Listing Rule 17.2, the Company advises that:

1. The voluntary suspension is requested in connection with a capital raising to be undertaken by the Company. The suspension is required to enable the capital raising to be undertaken in an orderly manner.
2. The Company expects the voluntary suspension to last for two trading days.
3. The Company requests that the voluntary suspension remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the capital raising and the commencement of trading on Monday, 6 November 2023.
4. The Company is not aware of any reason why its securities should not be suspended, or of any other information available at this stage that is relevant to the voluntary suspension.

Authorised for release by the Chair of Bod Science Limited.

ENDS

About Bod Science

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers. The Company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033